TerminatedNCT04722666
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicide prevention With Intent
Medication studyAges 18–65Multiple countriesDepression
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Birmingham and 38 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 20, 2021
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 199
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada, Argentina, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04722666
- Official title
Show the full official title
A Double-blind, Placebo-controlled, Randomized Dose-ranging Trial to Investigate Efficacy and Safety of Intravenous MIJ821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Farmington, United States · Oakland Park, United States
33 more locations
- Atlanta, United States
- Rockville, United States
- DeSoto, United States
- Buenos Aires, Argentina
- Fortaleza, Brazil
- São Paulo, Brazil
- Toronto, Canada
- Munich, Germany
- Frankfurt am Main, Germany
- Toyoake, Japan
- Bunkyo-ku, Japan
- Kodaira, Japan
- Seremban, Malaysia
- Kuala Lumpur, Malaysia
- Monterrey, Mexico
- Mazatlán, Mexico
- San Luis Potosí City, Mexico
- Groningen, Netherlands
- Pruszków, Poland
- Bialystok, Poland
- Gdansk, Poland
- Gmina Świecie, Poland
- Lodz, Poland
- Moscow, Russia
- Palma, Spain
- Barcelona, Spain
- Araba, Spain
- Taipei, Taiwan
- Istanbul, Türkiye
- Bursa, Türkiye
- Izmir, Türkiye
- Russia
- Türkiye
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Novartis Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including MIJ821 Intravenous Injection and Placebo Intravenous Injection.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
